Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 5
2019 4
2020 5
2021 7
2022 7
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Cited In for PMID: 28145883

29 results

Results by year

Filters applied: . Clear all
Page 1
Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.
Nouri M, Caradec J, Lubik AA, Li N, Hollier BG, Takhar M, Altimirano-Dimas M, Chen M, Roshan-Moniri M, Butler M, Lehman M, Bishop J, Truong S, Huang SC, Cochrane D, Cox M, Collins C, Gleave M, Erho N, Alshalafa M, Davicioni E, Nelson C, Gregory-Evans S, Karnes RJ, Jenkins RB, Klein EA, Buttyan R. Nouri M, et al. Oncotarget. 2017 Mar 21;8(12):18949-18967. doi: 10.18632/oncotarget.14850. Oncotarget. 2017. PMID: 28145883 Free PMC article.
ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer.
Qian C, Yang Q, Rotinen M, Huang R, Kim H, Gallent B, Yan Y, Cadaneanu RM, Zhang B, Kaochar S, Freedland SJ, Posadas EM, Ellis L, Vizio DD, Morrissey C, Nelson PS, Brady L, Murali R, Campbell MJ, Yang W, Knudsen BS, Mostaghel EA, Ye H, Garraway IP, You S, Freeman MR. Qian C, et al. bioRxiv [Preprint]. 2023 Oct 12:2023.09.28.560025. doi: 10.1101/2023.09.28.560025. bioRxiv. 2023. PMID: 37905039 Free PMC article. Preprint.
Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.
Kneppers J, Severson TM, Siefert JC, Schol P, Joosten SEP, Yu IPL, Huang CF, Morova T, Altıntaş UB, Giambartolomei C, Seo JH, Baca SC, Carneiro I, Emberly E, Pasaniuc B, Jerónimo C, Henrique R, Freedman ML, Wessels LFA, Lack NA, Bergman AM, Zwart W. Kneppers J, et al. Nat Commun. 2022 Nov 30;13(1):7367. doi: 10.1038/s41467-022-35135-2. Nat Commun. 2022. PMID: 36450752 Free PMC article.
Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaïve patients with metastatic castration-resistant prostate cancer.
Lee CL, Chang YH, Liu CY, Hsieh ML, Huang LK, Chu YC, Kan HC, Lin PH, Yu KJ, Chuang CK, Wu CT, Pang ST, Shao IH. Lee CL, et al. Investig Clin Urol. 2022 Sep;63(5):546-553. doi: 10.4111/icu.20210450. Investig Clin Urol. 2022. PMID: 36068000 Free PMC article.
29 results